Shares Homepage - BSE Sensex, NSE Nifty, Latest Prices, Live News, Company Search, Result Annoucements, Company News, Top stories, Gainers Losers, Top Performers, Market Commentary, Live Quotes, Bulk Deals
India's preferred Personal finance destination
Home Shares News Centre F&O Mutual Funds IPO Portfolio Commodity Loans Financial Planning Insurance About Us
Markets Companies Research Industries E-Mail Page
Wealth Tracker    Newsletter   Tax Corner NRI Centre Forums E-Mail Chat Masala Feedback
my Last 5 Scrips
Company BSE Price(Rs) % Chg
Axis Ban 407.55 2.31
Tata Stl 510.40 2.34
Bhel 226.85 0.70
Sslt 283.60 0.28
Tata Pow 87.95 2.81
Clear All Clear Last
Shares
NSE Live
Nifty Live Prices
Live Quotes
Top Gainers/Losers
Top 10 Turnover
No Delivery Stocks
BSE Live
BSE30 Live Prices
Live Quotes
Top Gainers/Losers
Top 10 Turnover
No Delivery Stocks
Market Pulse
Leaders
Laggards
FII Activity
Mutual Fund Activity
Meetings
Results Watch
Results Calendar
Results Announced
IPO Watch
Company
Snapshots
Quotes
Charts
Financials
Recent News
Broker Research
Meetings
Research Tutorial
Discussion Forum
Research
Research Reports
Sector Watch
Economy Watch
Snapshot-Strides Arcolab Limited
Strides Arcolab Limited
Sector:Pharmaceuticals Pharmaceuticals - Bulk Drugs and Formulations
BSE:532531NSE:STARBloomberg:STR@INReuters:STAR.BO
Market Lot: 1Face Value: 10ISIN Demat: INE939A01011
QuotesSnapshotChartsFinancialsResearchRecent News
Peer GroupAGM/AMMF HoldingDiscussion ForumBSE/NSE NoticesBSE/NSE Deals

 
 
Recent Developments
15-SEP-14 Strides Arcolab today announced that Gilead Sciences has licensed Strides to produce generic sofosbuvir and investigational single tablet regimen of ledipasvir/sofosbuvir for treatment of chronic hepatitis C. 26-AUG-14 Strides Arcolab, a pharmaceutical company manufacturing IP-led niche products, today announced that it has received approval from the United States Foods & Drugs Administration (USFDA) for Buspirone Hydrochloride tabl...   More..
Business Profile Future Plans
One To One
Recent news
Latest News
Strides Arcolab gets USFDA nod for Buspirone tablets  -IRIS 26-Aug-14
Previous

More


Brief Financials (in Rs. Mn.) 
Period ending (months)30-Jun-2014(6)31-Dec-2013(12)31-Dec-2012 (12)
Net sales 4303.097515.976132.89
Other Income607.6114390.601189.08
Total Income4910.7021906.577321.96
Cost of goods sold3952.756901.046163.01
OPBDIT957.9515005.531158.96
PAT-214.7035611.86559.86
Gross Block---
Equity capital595.66595.66588.04
EPS (Rs.)--9.55
DPS (Rs.)---
BV (Rs.)---
P/E range (x)--38.98 - 128.26
Debt / Equity (x)---
Operating margin (% of OI)19.568.515.8
Net margin (% of OI)-4.4162.6 7.6
Detailed Financials
Income 
Statement
Balance Sheet Latest 
Quarterly/Halfyearly
Ratio Analysis Share Statistics
Price Charts
Scrip Information



Registered Office
ADDRESS
No 201, Devavrata
Sector 17
Vashi
Navi Mumbai
Maharashtra-400 705
PHONE
(022) 2789 3199/ 5247
FAX
(022) 2789 2924/ 42
 
Board of Directors
NSE/BSE Announcements


Home | Shares | F&O | Mutual Funds | Loans | Insurance | News Centre
Wealth Tracker | Tax Corner | NRI Centre | E-mail | Search in myiris | Advertise
All rights reserved. IRIS Business Services Limited
Disclaimer